Table (E)T-1. Overview of case-control studies of HLA-distribution in Guillain-Barré syndrome

Study group / HLA-class / Cases vs controls / subgroups of patients and its HLA associations
Present Study / DRB1 / 164 Caucasian GBS patients / antecedent infection, anti-ganglioside antibodies, disease
DQB1 / 207 Caucasian controls / severity, clinical characteristics, electrophysiological criteria
HLA-DRB1*01 is associated with mechanical ventilation
Reference 26 / DRB1 / 47 Chinese AMAN patients / C. jejuni serology
DQB1 / 25 Chinese AIDP patients / DQ-beta RLD55-57/ED70-71 and DR-beta E9V11H13
DQA1 / 97 Chinese controls / associated with susceptibility to AIDP
Reference 24 / DRB1 / 47 Chinese GBS patients / C. jejuni serology, anti-GM1 antibodies
DQB1 / 50 Chinese controls / no significant differences
DQA1 / 7 Chinese C. jejuni enteritis
Reference 25 / A, B, C / 81 Japanese GBS patients / C. jejuni serology, anti-GM1 antibodies
DRB1, DQB1 / 87 Japanese controls / no significant differences
Reference 22 / A, B, C / 35 Japanese GBS patients / C. jejuni isolation, anti-ganglioside antibodies
DRB1, DQB1 / 58 Japanese MFS patients / significant association with HLA-B54 and Cw1 and C. jejuni + GBS
112 Japanese controls
Reference 27 / DRB1, DRB3 / 12 Chinese AIDP patients / no significant differences between AIDP or AMAN vs controls
DRB4, DRB5 / 31 Chinese AMAN patients
DQB1, DPB1 / 34 Chinese controls
Reference 29 / DRB1, DQB1 / 97 Caucasian GBS patients / C. jejuni serology
7 Caucasian MFS patients / DQB1*03 associated with C. jejuni +GBS group
100 Caucasian controls
Reference 17 / A, B, C / 32 Japanese MFS/GBS patients / no subgroups tested
DR, DQ / with IgG anti-GQ1b antibodies / no significant associations
51 Japanese controls
Reference 28 / A, B / 30 Slavic GBS patients / no subgroups tested
DR / 150 Slavic controls / no significant association
Reference 32 / A, B, C / 5 Japanese C. jejuni+ / no subgroups tested
GBS patients / Association between HLA-B35 and C. jejuni and anti-GM1
3090 Japanese controls / positive patients with an acute axonal polyneuropathy
Reference 20 / DR, DQ, DP / 49 Swedish GBS patients / severity of disease, response to plasmapheresis
100 Swedish controls / no significant associations
Reference 31 / A, B, C / 89 Caucasian GBS patients / severity of disease, prognosis, antecedent infection
DR / 210 Caucasian controls / no associations
Reference 19 / A,B / 32 Egyptian GBS patients / no subgroups tested
234 Egyptian controls / A3-B8 significantly increased in GBS
Reference 21 / A, B, C / 92 USA GBS patients /

A/NJ/76 influenza vaccination

100 USA controls / no significant association
Reference 18 / DR / 38 Mexican GBS patients / no subgroups tested
100 Mexican controls / HLA-DR3 significantly increased in GBS
Reference 23 / A, B / 18 European GBS patients / no subgroups tested
D / 103 European controls / no significant associations
Reference 30 / A, B / 22 Australian GBS patients / no subgroups tested
D / 322 Australian controls / no significant association
Reference 16 / A, B / 59 Caucasian GBS patients / no subgroups tested
561 Caucasian controls / no significant association

In this table the significant HLA-associations are represented only. The subgroups tested are represented in italics. GBS: Guillain-Barré syndrome, AMAN: acute motor axonal neuropathy, AIDP: acute inflammatory demyelinating neuropathy, C. jejuni: Campylobacter jejuni, MFS: Miller Fisher syndrome, * present study